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INTRODUCTION
Vasoconstrictors like adrenaline in local anaesthetics are 
associated with more drug interactions than any other 
drug in Dentistry1 with an incidence of adverse reactions 
ranging from 2.5%-11%.2 Therefore, understanding the 
physiological and pharmacological effects, interactions 
with other drugs, and dosages are important in day to day 
dental practice.
 
Local anaesthetics are vasodilators, hence the addition 
of a vasoconstrictor like adrenaline provides the following 
advantages: improves the anaesthetic onset and duration, 
reduces bleeding, and decreases the systemic absorption 
rate of local anaesthetics by reducing the plasma 
concentration.2,3 However, adrenaline is unstable and 
therefore an antioxidant is added to prevent it oxidizing. 
Sodium bisulphite is the preservative most commonly 
added to local anaesthetics. Of course, patients allergic to 
sulphites will now react to a local anaesthetic containing 
sodium bisulphites.
 
DOSAGE
Calculating the dose of vasoconstrictor is different 
from ascertaining the local anaesthetic dosage in that 
vasoconstrictors are expressed as a dilution ratio and 
are not weight-dependent. In local anaesthetics, the 
adrenaline in dilution ratios of 1:80000 (Xylotox E80A, 
Adcock Ingram; Xylestesin, 3M), 1:100 000 (Ubistesin 
forte, 3M; Septocaine, Septodont) and 1:200000 
(Ubistesin 3M; Septocaine, Septodont) are generally 
the most commonly used concentrations in dentistry. 
Adrenaline concentrations are generally expressed as 
1:1000 which is 1mg/ml. Therefore, a local anaesthetic 
with 1:100000 adrenaline concentration will translate to 
0.01mg/ml resulting in a 1.8ml local anaesthetic cartridge 
containing 0.018mg adrenaline. A 1:200000 will therefore 
contain a concentration of 0.005mg/ml translating to 
approximately 0.01mg per cartridge of local anaesthetic. 
The maximum dose of adrenaline in healthy patients is 
0.2mg per appointment (approximately 10 cartridges 
of 1:100000 local anaesthetic). However, in medically 
compromised patients, such as those having cardiac risk, 
the recommended maximum dosage of adrenaline is 0.04 
mg i.e. two cartridges of 1:1000000 local anaesthetic. 
The American Heart Association and the American Dental 
Association have stated "the typical concentrations of 
vasoconstrictors contained in local anaesthetics are not 
contraindicated in cardiovascular disease so long as 
preliminary aspiration is practiced, the agent is injected 
slowly, and the smallest effective dose is administered".4 
Adrenaline 1:100,000 caused more sympathomimetic side 
effects than did 1:200,000 adrenaline concentration5 thus 
it is logical to use this lower concentration of adrenaline 
when possible. In several European and Asian countries, 
adrenaline concentrations of 1:300000 and 1:400000 are 
now available in dental cartridges.6 Furthermore, using 
a lower concentration of adrenaline like 1:200000 does 
not seem to compromise the anaesthetic efficacy of the 
local anaesthetic.7-9 In fact, 1:200000 solutions should be 
the preferred choice of adrenaline concentration in the 
absence of significant differences in performance with the 
1:100000 solution.10 For patients undergoing periodontal 
surgery, 4% articaine with either adrenaline 1:100000 or 
1:200000 concentration provides excellent surgical pain 
control. However, the 4% articaine 1:100000 adrenaline 
concentration has the additional advantage of providing 
better visualization of the surgical field because there is 
less bleeding.11 
ADRENALINE AND DRUG INTERACTION
Another problem associated with adrenaline is that it can 
interact with some of the drugs that the patient may be 
taking. In this instance the most commonly affected drugs 
are the non-selective beta blockers, some antidepressants 
and “street drugs” (Table 1).
NON-SELECTIvE BETA BLOCKERS
Non-selective beta blockers like propranolol (Inderal) and 
nadolol (Corgard) are used as anti-hypertensive drugs 
or to control migraines. Vasoconstrictors administered 
to patients on non-selective beta blockers can result 
in uncompensated peripheral vasoconstriction as a 
result of unopposed stimulation of alpha 1 receptors, 
leading to increase in blood pressure, bradycardia and 
headaches.4,12,13
Cases have been recorded in both the dental and medical 
literature where the magnitude of the blood pressure 
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increased was alarming and potentially life threatening.13 
Therefore, in patients on non-selective beta blockers 
requiring simple restorative procedures, complete 
avoidance of adrenaline seems rational. For more 
complex procedures for which haemostasis or a more 
prolonged duration of local anaesthesia is required, the 
initial vasoconstrictor dose should be kept to an absolute 
minimum such as one-half of a dental cartridge with 
1:100000 or preferably 1:200000 and injected carefully to 
avoid intravascular administration. The vital signs of the 
patient should be monitored before further administration. 
If there is no change in cardiovascular status, additional 
cartridges can be injected individually at five-minute 
intervals. Adrenaline containing retraction cord must be 
avoided in a patient taking a non- selective β-antagonist.
TRICYCLIC ANTIDEPRESSANTS 
Tricyclic antidepressants like imipramine and amitriptyline 
inhibit the uptake of adrenaline at the neuronal level, resulting 
in increased concentrations of the catecholamines at the 
sympathetic neuronal junction.14 A maximum dose of 0.04 mg, 
(equivalent to two cartridges of 1;100000 local anaesthetic) 
of exogenous adrenaline is proposed for patients on tricyclic 
antidepressants.15 Using a lower concentration of 1:100000or 
less, eg. 1:200000, is preferable and in a dosage which is no 
more than one-third the normal maximum which would be 
given, should preclude any problem that could arise from a 
tricyclic drug interaction.1
The interactions of vasoconstrictors with general anaesthet-
ics like halothane, thiopental and barbiturates can increase 
the dysrhythmic effects of dental vasoconstrictors. The cli-
nician needs to inform the anaesthetist before administer-
ing a local anaesthetic with vasoconstrictor, and to restrict 
the dose to the limit recommended for the vasoconstrictor 
according to general anaesthetic procedures: halothane 
(2.2µgkg for halothane, 3.5µg/kg for enflurane and 5.5µg/
kg for isoflurane).1,15 A reported death under halothane an-
aesthesia caused by adrenaline in gingival retraction cord 
reinforces the need to adhere to recommended doses of 
adrenaline under general anaesthesia.
“STREET DRUGS”
Methamphetamines and cocaine have sympathomimetic 
effects and can interact with adrenaline in local 
anaesthetics. Vasoconstrictors in combination with cocaine 
or methamphetamines increase the risk of hypertensive 
crises, stroke and myocardial infarction.4 Elective dental 
treatment should be postponed for at least 24 hours after 
the last cocaine use to allow elimination of the drug.3 
ADRENALINE AND THE MEDICALLY 
COMPLEx PATIENT
Adrenaline is both a hormone and a neurotransmitter 
belonging to sympathomimetic drugs that can mimic 
sympathetic nervous system mediators.6 It provides direct 
stimulation of the adrenergic receptors. Clinicians need to 
be aware of its effect on the sympathetic nervous system 
especially in medically compromised patients as certain 
modifications must be made (Table 1). A joint statement 
of the American Dental Association and American Heart 
Foundation on vasoconstrictors provides the following 
advice: “Vasoconstrictors should be used with extreme 
care to avoid intravascular injection. The minimum possible 
amount of vasoconstrictor should be used”.6
CARDIOvASCULAR DISEASES
In the presence of ischaemic heart disease, elective dental 
treatment is contraindicated in the following situations: 
patients with unstable angina, recent myocardial infarction 
(less than six months), recent coronary artery bypass 
surgery (less than three months).16
If emergency dental treatment is necessary, medical 
consultation is required and adrenaline dosages should be 
limited to one to two cartridges of 1:100000 solution (0.018 
to 0.036 mg of adrenaline).16,17 Similarly, in patients with 
stable angina, vasoconstrictors should be limited to one 
to two cartridges.16 Vasoconstrictors are contraindicated 
in patients with severe arrhythmias.10 Digoxin, prescribed 
to increase the heart’s contractile force, has a narrow 
therapeutic index and may precipitate a cardiac arrhythmia 
when used concurrently with vasoconstrictors.16,17
STROKE
Use of adrenaline should be deferred for patients who 
have suffered a cerebrovascular accident, or stroke within 
the last six months. After that time, doses of adrenaline 
should be limited to less than 0.036 mg, equivalent to two 
cartridges of local anaesthetic with 1:100000 adrenaline 
concentration.16,17
HYPERTHYROIDISM
The use of adrenaline in local anaesthetics should be 
avoided, or at least minimized to one to two cartridges, in 
the untreated or poorly controlled hyperthyroid patient.18 
Although the theoretical risk of thyroxine - adrenaline 
potentiation is serious, no clinical case has been 
reported.10
Table 1:  Precautions regarding adrenaline usage in local anaesthetics.
Contraindications to vasoconstrictors in dentistry Precautions to the use of vasoconstrictors in dentistry
Heart diseases:•	
Unstable angina, Recent myocardial infarction, Recent 
coronary artery bypass surgery, Refractory arrhythmias, 
Untreated or uncontrolled congestive heart failure.
Untreated or uncontrolled severe hypertension,
Uncontrolled hyperthyroidism•	
Uncontrolled diabetes•	
Sulphite allergies•	
Steroid-dependent asthma•	
Pheochromocytoma•	
Patients taking tricyclic antidepressants•	
Patients taking phenothiazine compounds•	
Patients taking monoamine oxidase inhibitors•	
Patients taking nonselective Beta-blockers•	
Cocaine abusers•	
Patients undergoing general anaesthesia with Halothane•	
Patients taking Digoxin•	
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CORTICOSTEROID-DEPENDENT ASTHMA
Administration of local anaesthetic with vasoconstrictors in 
cortico-dependent asthma patients may result in a higher risk 
of sulphite allergy. An anaesthetic without vasoconstrictor, 
and thus without bisulphite, is indicated.4,10,17
PHEOCHROMOCYTOMA
A tumour of the adrenaline medulla, characterized by the 
presence of catecholamine-producing tissue, constitutes 
an absolute contraindication to the administration of 
vasoconstrictors.10
BONE IRRADIATION
It is desirable to avoid the use vasoconstrictors with a local 
anaesthetic when a patient is receiving irradiation of bone.10
CONCLUSION
A thorough understanding of the pharmacologic 
interactions between adrenaline and vasoconstrictors is 
important to avoid untoward reactions in patients. 
A lower concentration like 1:200000 provides similar 
vasoconstriction and may be preferred especially for 
medically compromised patient.
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